Literature DB >> 28786486

Markov chain Monte Carlo analysis for the selection of a cell-killing model under high-dose-rate irradiation.

Yusuke Matsuya1, Takaaki Kimura1, Hiroyuki Date2.   

Abstract

PURPOSE: High-dose-rate irradiation with 6 MV linac x rays is a wide-spread means to treat cancer tissue in radiotherapy. The treatment planning relies on a mathematical description of surviving fraction (SF), such as the linear-quadratic model (LQM) formula. However, even in the case of high-dose-rate treatment, the repair kinetics of DNA damage during dose-delivery time plays a function in predicting the dose-SF relation. This may call the SF model selection into question when considering the dose-delivery time or dose-rate effects (DREs) in radiotherapy and in vitro cell experiments. In this study, we demonstrate the importance of dose-delivery time at high-dose-rate irradiations used in radiotherapy by means of Bayesian estimation.
METHODS: To evaluate the model selection for SF, three types of models, the LQM and two microdosimetric-kinetic models with and without DREs (MKMDR and MKM) were applied to describe in vitroSF data (our work and references). The parameters in each model were evaluated by a Markov chain Monte Carlo (MCMC) simulation.
RESULTS: The MCMC analysis shows that the cell survival curve by the MKMDR fits the experimental data the best in terms of the deviance information criterion (DIC). In the fractionated regimen with 30 fractions to a total dose of 60 Gy, the final cell survival estimated by the MKMDR was higher than that by the LQM. This suggests that additional fractions are required for attaining the total dose equivalent to yield the same effect as the conventional regimen using the LQM in fractionated radiotherapy.
CONCLUSIONS: Damage repair during dose-delivery time plays a key role in precisely estimating cell survival even at a high dose rate in radiotherapy. Consequently, it was suggested that the cell-killing model without repair factor during a short dose-delivery time may overestimate actual cell killing in fractionated radiotherapy.
© 2017 American Association of Physicists in Medicine.

Entities:  

Keywords:  Markov chain Monte Carlo simulation; dose-delivery time; fractionated irradiation; linear-quadratic model; microdosimetric-kinetic model

Mesh:

Year:  2017        PMID: 28786486     DOI: 10.1002/mp.12508

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  5 in total

1.  Investigation of dose-rate effects and cell-cycle distribution under protracted exposure to ionizing radiation for various dose-rates.

Authors:  Yusuke Matsuya; Stephen J McMahon; Kaori Tsutsumi; Kohei Sasaki; Go Okuyama; Yuji Yoshii; Ryosuke Mori; Joma Oikawa; Kevin M Prise; Hiroyuki Date
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

2.  A Model for Estimating Dose-Rate Effects on Cell-Killing of Human Melanoma after Boron Neutron Capture Therapy.

Authors:  Yusuke Matsuya; Hisanori Fukunaga; Motoko Omura; Hiroyuki Date
Journal:  Cells       Date:  2020-04-30       Impact factor: 6.600

3.  Intensity Modulated Radiation Fields Induce Protective Effects and Reduce Importance of Dose-Rate Effects.

Authors:  Yusuke Matsuya; Stephen J McMahon; Mihaela Ghita; Yuji Yoshii; Tatsuhiko Sato; Hiroyuki Date; Kevin M Prise
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

4.  4-Methylumbelliferone administration enhances radiosensitivity of human fibrosarcoma by intercellular communication.

Authors:  Ryo Saga; Yusuke Matsuya; Rei Takahashi; Kazuki Hasegawa; Hiroyuki Date; Yoichiro Hosokawa
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

5.  Tumor radioresistance caused by radiation-induced changes of stem-like cell content and sub-lethal damage repair capability.

Authors:  Roman Fukui; Ryo Saga; Yusuke Matsuya; Kazuo Tomita; Yoshikazu Kuwahara; Kentaro Ohuchi; Tomoaki Sato; Kazuhiko Okumura; Hiroyuki Date; Manabu Fukumoto; Yoichiro Hosokawa
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.